Skip to main content

Table 6 Results: mean cost per patient (3% discount)

From: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

 

Mean cost per treated patient

Parameter

Prophylaxis

Non prophylaxis

Difference

- BPD

6,517.26

6,003.79

513.47

- < 33 weeks

5,819.65

4,429.13

1,390.52

- 33–35 weeks

6,199.79

3,979.70

2,220.09

Total

6,244.20

4,867.70

1,376.50